Pendidikan :
SMP - SMA : Kolese KANISIUS, 1994
Dokter Umum : FK TRISAKTI, 2002
Spesialis Penyakit Dalam (Internist) : FKUI, 2009
Konsultan Penyakit Tropik & Infeksi : FKUI / PAPDI, 2013
Pekerjaan :
Bendahara Pengurus Besar Perhimpunan Konsultan Penyakit Tropik dan
Infeksi Indonesia (PB PETRI)
PP. PERDALIN
INTERNIST - INFECTIOUS DISEASE (ID) CONSULTANT
Amebiasis
cIAI, Acute Diarrhea : E.coli & ESBL
MDR Salmonella typhi (MDR-ST)
Drug Resistant Microorganism
AMEBIASIS
Amebiasis is a disease caused
by the parasite Entamoeba
histolytica
CDC,2010
LIFE CYCLE
CDC,2010
Pathogenesis of Amebiasis
Adhesins
Amebapores
Proteases
Cantellano ME, Palomo AM, Clin Microbiol Rev : 2000 ; 13(2) : 218-321
Amebiasis Clinical Presentation
Amebic colitis
Fever (10-30%)
Weight loss (40%)
Diffuse abdominal tenderness (12-85%)
Heme-positive stools (70-100%)
Abdominal pain, distension, and rebound tenderness likely in
fulminant colitis
Cerebral amebiasis
Occurring in 0.6% of amebic liver abscess cases, abrupt
onset of nausea, vomiting, headache, and mental status
change should prompt rapid investigation for CNS
involvement.
Progression can be very rapid.
E.coli 55%
K. pneumoniae 20%
E.coli and K.pnemoniae P. aeruginosa 5%
are common in most E. cloacae 5%
community acquired Intra
A.baumanii 2%
Abdominal infections
0% 20% 40% 60%
Gyr A Fluorquinolone
Gene Resistance
MDR-ST
Betalactamase
TEM-1 Type A
Gene ESBL
Yoon HJ, Cho SH, Kim SH, A case of MDR Salmonella enterica serovar typhi treated with a bench to bedside
Approach, Yonsei J Med, 2009 : 50(1) : 147-51
Native
Organisms
Perl TM. Gram Negative Bacterial Resistance in Healthcare: The Brave New World Healthcare
Resistance in Gram-negatives
MDR (multidrug-resistant)
Resistance to 3 classes of antimicrobial agents
CR( carbapenems resistant)
Resistant to imipenem or meropenem
PDR (pandrug-resistant)
Resistance to all*
Resistant Strains
Rare
Antimicrobial
Exposure
Resistant Strains
Dominant
Resistant Bacteria
PP. PERDALIN
Adequate antimicrobial treatment in critically ill
patients
Changes to
Empiric Treatment
Pathogen (de-escalation) Timely
Coverage Initiation
(appropriate) (early)
Optimal
Correct
Therapy Correct
Dose Route
(adequate) (adequate)
Increased Survival
Persistent effects
Post Antibiotic Effect (PAE)
MIC
Minimum inhibitory concentration
in mg/L or ug/mL
Is the lowest concentration in a series
of twofold concentrations that will
inhibit the growth of a microorganism,
as measured by the naked eye.
PK/PD parameters affecting antibiotic efficacy in
vivo
Concentration Cmax:MIC
Time dependent
AUC:MIC T>MIC (CEF)
Concentration dependent
Cmax>MIC (AM)
AUC/MIC (FQ)
T>MIC
MIC
PAE
0
Time (hours)
MIC = minimum inhibitory concentration; AUC = area under the curve; T = time;
PAE = post antibiotic effect
Antibiotic Characteristic base on PKPD
Cmax = Peak Concentration Dependent
Cmax / MIC AUC / MIC
Aminoglycosides1,2 Aminoglycosides2
Fluoroquinolones1,2 Fluoroquinolones1,2
Oxazolidanones1,2
Glycopeptides2
Concentration
Lincosamides2
Lipopeptides1,2
Tetracyclines2
Macrolides2
MIC
Penicillins1
Cephalosporins1 T > MIC
Carbapenems1 Cmin = Trough
Macrolides1,2
Glycopeptides2
Lincosamides2
Time (hours)
MIC
0
Time (hours)
Cmax = maximum plasma concentration
T>MIC (β-lactams)
Concentration
MIC
T>MIC
0
Time (hours)
Turnridge. Clin Infect Dis 1998;27:1022; Manduru, et al. Antimicrob Agents Chemother 1997;41:2053–2056;
Tam, et al. J Antimicrob Chemother 2002;50:425–428; Tam, et al. Antimicrob Agents Chemother 2005;49:4920
24 hour Area Under Curve
24 H AUC : cummulative dosage in 24 H
Related to efficacy and drug toxicity
Concentration Target Attaintment : 24 H AUC/MIC : 125
if MIC = 2 24 H AUC : 250
average concentration 250/24 : 10 ug/mL
MIC
0 Time
Time (hours)
Ambrose, et al. Antimicrob Agents Chemother 2001;45:2793–2797;
Forrest, et al. Antimicrob Agents Chemother 1993;37:1073–1081
Cunha,2010
In VITRO
MIC90
CLSI
EUCAST
CLINICIAN
Blood Lining Level
Colonization Pathogen